Archives February 2025

ABB India
ABB India Q4 Results: Net Profit Surges 56% to ₹528.41 Crore– Financial Growth & Industry Innovations

Business and Industry Overview:  

ABB is a Swiss technology leader in electrification and automation. Its solutions connect engineering know-how and software to optimize how things are manufactured, moved, powered, and operated. ABB has over 140 years of excellence. With more than 105,000 employees, it is driving innovations that accelerate industrial transformation. ABB India Limited is an integrated power equipment manufacturer supplying a complete range of engineering, products, solutions, and services in Automation and Power technology. 

With the advancement in artificial intelligence, most of the work that does not require human intelligence is done by automation. The industry is booming on an developing country like india as there is a huge require of skills workforce at a cheaper rate to strive in a industry with so much competition. The India Industrial Automation Market size is estimated at USD 17.28 billion in 2025, and is expected to reach USD 33.64 billion by 2030, at a CAGR of 14.26% during the forecast period (2025-2030). And ABB provides inovative solutions and is a major player in the industry. It is in various industrial automation segments like manufacturing, power generation, infrastructure, and more.  

Segmental information:  

Electrification: ABB’s Electrification business offers a wide range of products, digital solutions, and services, from substation to socket, enabling safe, smart, and sustainable electrification. Offerings encompass digital and connected innovations for low- and medium-voltage, including EV infrastructure, solar inverters, modular substations, distribution automation, power protection, wiring accessories, switchgear, enclosures, cabling, sensing, and control. Its offerings include digital and connected innovations for low- and medium-voltage, including EV infrastructure, solar inverters, modular substations, distribution automation, etc.  

Motion: ABB’s Motion business is the largest supplier of drives and motors globally. They provide customers with a complete range of electrical motors, generators, drives, and services, as well as integrated digital powertrain solutions. They also serve a wide range of automation applications in transportation, infrastructure, and the discrete and process industries. It is the largest supplier of drives and motors globally. It has a complete range of electrical motors, generators, drives and services, as well as integrated digital powertrain solutions.  

Process Automation: ABB’s Process Automation business offers a broad range of solutions for process and hybrid industries, including industry-specific integrated automation, electrification and digital solutions, control technologies, software, and advanced services, as well as measurement & analytics and marine offerings. Process automation is 2 in the market globally. Working closely with customers, ABB’s Process Automation business is writing the future of safe and smart operations. They offer a broad range of solutions for process and hybrid industries, including industry-specific integrated automation, electrification and digital solutions, control technologies, software and advanced services.  

Robotics & Discrete Automation: ABB’s Robotics & Discrete Automation business provides value-added solutions in robotics, machine, and factory automation. Our integrated automation solutions, our application expertise across a wide scope of industries, and our global presence deliver tangible customer value. Our focus on innovation includes extensive work in artificial intelligence, an ecosystem of digital partnerships, and the expansion of our production and research capabilities through our $150-million investment in a new world-class robotics factory in Shanghai. This segment provides value-added solutions in robotics, machine and factory automation.  

Subsidiary information: 

ABB India is a subsidiary of ABB Ltd which is a leading electrification and automation company globally. It derives significant benefits from its parent in the form of access to centralised R&D facilities of ABB for which it pays royalty to ABB. ABB also provides management support through delegates on the board of ABB India. [1] 

Latest Stock News: 

ABB has recently introduced ABB Ability SmartMaster, an asset performance management platform for real-time verification and condition monitoring of industrial instrumentation. Additionally, in February 2024, the company launched the ACH180 compact drive, designed for HVACR applications to enhance energy efficiency. In a strategic move to advance 3D printing in the Indian construction sector, ABB Robotics partnered with Simpliforge Creations, aiming to improve automation and efficiency. Furthermore, ABB expanded its digital presence with ABB eMart, an e-commerce marketplace featuring 6,000+ products, providing better accessibility for B2B and B2C customers in Electrification, Motion, and Industrial Automation. 

ABB India achieved its highest-ever annual order book of ₹13,079 crore and revenue of ₹12,188 crore for the full year. In Q4, the company’s net profit rose to ₹528.41 crore, up from ₹338.68 crore a year ago, driven by 22% revenue growth to ₹3,364.93 crore. This marked the highest December-quarter revenue in five years. Sequentially, net profit increased by 20%, while revenue grew 16% compared to the previous quarter. The company’s board also approved a final dividend of ₹33.50 per share for the financial year ending December 31, 2024, subject to shareholder approval. ABB India follows a January-December financial year. 

Q3 highlights : 

  • Revenue grew 22% YoY to ₹3,364.93 crore; net profit surged 56% YoY to ₹528.41 crore. 
  • Net profit increased 20% QoQ, while revenue rose 16% QoQ. 
  • Board approved a final dividend of ₹33.50 per share, pending shareholder approval. 

Financial Summary: 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 2,757.00 3,365.00 10,447 12,188 
Expenses 2,340 2,708 8,945 9,883 
EBITDA 417 657 1,501.00 2,305.00 
OPM 15% 20% 14% 19% 
Other Income 71 83 289 350 
Net Profit 339.00 528.00 1,242 1,872 
NPM 12.30 15.69 11.89 15.36 
EPS 15.98 24.94 58.61 88.33 

Hexaware Technologies
Hexaware Technologies IPO: Shares Listed at 5% on High

IPO Overview 

Hexaware Technologies, a leading information technology services provider, launched its ₹8,750 crore IPO from February 12 to 14, with a price band of ₹674–708 per share. The offering was entirely an Offer for Sale (OFS) by its promoter, CA Magnum Holdings, affiliated with The Carlyle Group. The IPO was oversubscribed 2.66 times. The shareholders pattern is as follows: the Qualified Institutional Buyers (QIBs) subscribed 9.09x, while Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs) subscribed at 20% and 11%, respectively. The company raised ₹2,598 crore from institutional investors, with a valuation exceeding ₹43,000 crore at the upper price band. The book-building procedure of the IPO was managed by Kotak Mahindra Capital Company, Citigroup Global Markets India, JP Morgan India, HSBC Securities & Capital Markets Pvt Ltd, and IIFL Securities Ltd. 

Market Position & Industry Analysis 

The Information Technology (IT) &  Business Process Management (BPM) sector plays a crucial role in India’s economy, contributing 7% to the GDP as of FY24. India has one of the largest internet consumer and, at the same time, has the lowest internet costs globally. With this, India is next for the next phase of IT growth. The Digital India Programme has strengthened digital infrastructure and access, driving rapid digital adoption through government initiatives, private sector innovation, and emerging digital applications. These advancements are creating economic value and enhancing citizen empowerment. India’s global standing in innovation has also improved, ranking 40th in the 2022 Global Innovation Index. Hexaware Technologies provides IT services in business process services, digital IT operations, cloud, data & AI, application services, and cybersecurity. The company operates across 50 offices in 19 countries, with a diverse workforce of 90 nationalities and approximately 33% women representation. The company competes with major IT service providers such as Tata Consultancy Services (TCS), Infosys, Wipro, and HCL Technologies. The IT services sector is witnessing rapid digital transformation and increasing demand for AI, cloud computing, and automation. Hexaware’s strategic focus on cloud and AI-driven solutions positions it well for future growth. 

Financials & Valuation 

Hexaware’s market capitalization stood at ₹44,422.48 crore post-listing and later rose to ₹46,285.06 crore as the stock gained 2.17% to ₹761.65 per share. The stock opened at ₹745.50 on the NSE, reflecting a 5.3% premium over the issue price, while on the BSE, it listed at ₹731, a 3.25% premium. By the end of the first trading day, shares settled at ₹755.75 on NSE (6.74% above the IPO price) and ₹763.85 on BSE (7.89% above the IPO price). During intraday trading, the stock peaked at ₹788, reflecting an 11.3% gain. Hexaware’s valuation, compared to industry peers, indicates strong growth potential and a focus on scalable digital transformation services.  

Investor Sentiment & Analyst Insights 

Despite a subdued initial listing, Hexaware Technologies’ stock gained traction due to strong investor interest. The oversubscription of the IPO, particularly by institutional investors, indicates confidence in the company’s future growth. The IT services sector’s expansion, coupled with Hexaware’s cloud and AI-driven strategy, presents growth opportunities. However, potential risks include global economic slowdowns, intense competition from larger IT players, and evolving regulatory challenges. The grey market premium (GMP) trends suggested moderate demand pre-listing, which translated into a stable yet promising listing performance. Overall, the IPO’s strong institutional backing and Hexaware’s strategic focus make it an attractive investment opportunity for long-term investors.  

Investors who did not receive the subscription should wait for the company’s quarterly results to assess its performance and decide whether to own the shares.  

Godfrey Phillips India Ltd
Godfrey Phillips India Ltd: A Strong Player in the FMCG & Tobacco Industry with High Growth Potential

Business and Industry Overview: 

Godfrey Phillips India Limited is a flagship company of Modi Enterprises – KK Modi Group. The company is a major player in the FMCG sector, primarily known for its cigarette and tobacco business. It holds a major market share of 14 percent in India’s domestic cigarette industry. It also manufactures popular brands like Four Square, Red & White, and Cavanders, along with producing Marlboro under an agreement with Philip Morris. 

The tobacco business contributes 93% of total revenue (Q1 FY25), with 70% from domestic sales and 23% from international operations. It operates across 40+ countries. The non-tobacco segment (7%) includes confectionery (Funda brand) and retail (24Seven convenience stores). However, in April 2024, the company announced its exit from the retail business, incurring a ₹60 crore loss from closure costs. 

CRISIL forecasts 7-9% revenue growth for the FMCG sector in the current FY25, driven by increased volume and rural demand recovery. Fast-moving Consumer Goods (FMCG) sector is India’s fourth-largest sector and has been expanding at a healthy rate over the years because of rising disposable income, a rising youth population, and rising brand awareness among consumers. With household and personal care accounting for 50% of FMCG sales in India, the industry is an important contributor to India’s GDP. Godfrey Phillips is the second largest cigarette manufacturer in India by market capitalisation and by revenue. It has a market share of 14% in the domestic industry.  

Latest Stock News: 

There was a spike in the market price of Godfrey Phillips of  71% in one month and 49% year-to-date (YTD) after it announced its Q3 results on 13 February. Godfrey Phillips India reported a consolidated net profit of ₹315.84 crore in the fiscal third quarter ended December 2024, registering a growth of 48.73% from ₹212.35 crore in the same period last fiscal year. The company’s consolidated revenue from operations in Q3FY25 increased 27.42% to ₹1,895.52 crore from ₹1,487.54 crore, year-on-year (YoY). At the operational front, EBITDA in the December quarter grew 57.6% to ₹358.8 crore from ₹227.7 crore, while EBITDA margin expanded to 22.6% from 18.2%, YoY. 

Potentials: 

Godfrey Phillips is building on export markets. It is strengthening its partnership with Philip Morris International for Malro cigarettes in India. It is leveraging its distribution by entering into product supply agreements. Though there is a surge in the market price of the company in the past 5 days and positive Q3 results, there are a few risk factors for the company.  Regulatory risks, such as higher tobacco taxes, health-related restrictions, and ESG concerns, pose challenges. The retail business exit in April 2024 resulted in a ₹60 crore impairment loss, but it allows the company to focus on its core tobacco and confectionery businesses. Future expansion will be driven by geographic expansion in new cigarette markets and strengthening its export portfolio. 

Analyst Insights: 

Key Financial Metrics (Q3 FY25) 

Revenue Growth: +64% (FY22-FY24), driven by domestic cigarette volumes and export growth. 

Operating Margin: Declined from 24% to 20% due to rising tobacco prices and a higher share of low-margin unmanufactured tobacco. 

Retail Business Exit: ₹60 crore impairment loss recorded in Q1 FY25. 

Market Cap: ₹_33,900 Crore 

P/E Ratio: 32.4 

The company has reduced its debt and has also reported good Q3 results. It has also maintained a healthy dividend payout of 33.1%. The company has strong revenue growth, a dominant market position, and international expansion opportunities, making it a long-term positive prospect. However, regulatory uncertainties, margin pressures, and ESG concerns are key risks. The exit from the retail business is a strategic move to focus on core strengths. 

PB Fintech Ltd
PB Fintech Ltd: Strong Market Leader in Digital Insurance & Lending– 52-Week Low & Stock Analysis

Business and Industry Overview: 

PB Fintech Limited is a leading Indian fintech company based in Gurgaon. It operates in two segments, Insurance Web Aggregator/Insurance Broker services and Other Services. It has two main core platforms that are Policybazaar and Paisabazaar, which offer digital insurance and lending products. It was founded in 2008 by Yashish Dahiya, Alok Bansal, and Avaneesh Nirjar. It was initially focused on insurance comparison but later expanded into direct insurance sales and digital lending. PolicyBazaar is India’s largest digital insurance marketplace (93% market share), providing health, term, motor, and travel insurance. As of Q2 FY25, it has 86.9M registered users and has sold 46.8M+ insurance policies. PaisaBazaar is India’s largest credit product comparison platform, serving 47M+ consumers across 820+ cities, facilitating loans, credit cards, and credit score services. Apart from these two, they have PB Partners a B2A2C (Business-to-Agent-to-Consumer) platform enabling 250,000+ insurance agents through a Platform-as-a-Service (PaaS) model. The company operates under regulations from the Insurance Regulatory and Development Authority of India (IRDAI) and has expanded internationally to the UAE. 

PB Fintech Limited operates an online platform for insurance and lending products in India. The company offers Policybazaar, an online platform to buy and sell insurance products, such as health, term, motor, and travel insurance products; savings and investment products; and B2B offerings for consumers and insurance partners. It also provides Paisabazaar, an independent digital lending platform that enables consumers to compare, choose, and apply for personal credit products, including personal, business, and home loans, as well as credit cards and loans against property. In addition, the company offers call center and online healthcare-related services; online marketing, consulting, and support services; and support services in motor vehicle claims and related assistance, as well as engages in the online, offline, and direct marketing of insurance products. 

Policybazaar.com has tie-ups with insurance companies that help it procure information such as prices, benefits, insurance cover, etc. directly from the insurers. Users can use the Policybazaar website or app to research, compare and buy insurance policies from over 40 insurance providers. Policybazaar has companies that offer car insurance, health insurance, life insurance, corporate insurance, and travel insurance as its business partners. 

The Insurance Regulatory And Development Authority of India regulates the insurance web aggregation business of Policybazaar. The company is registered as an insurance web aggregator under the Insurance Web Aggregator Regulations, 2017. 

India secured the third position globally in fintech funding despite a 33% decline in YoY funding, which dropped to Rs. 16,475 crore (US$ 1.9 billion) in 2024, according to Tracxn’s Annual India Fintech Report. This reduction in funding reflects a broader slowdown in demand and ongoing geopolitical challenges. The fintech sector raised Rs. 24,279 crore (US$ 2.8 billion) in 2023 and Rs. 48,558 crore (US$ 5.6 billion) in 2022, underlining a significant decline over the past two years. Despite this, India remains one of the top three globally funded fintech ecosystems, only trailing the US and the UK. 

With india moving towards to a cashless economy and everything shifting to digital, there is a massive surge in the fintech industry in India and PB Limited is one of the first company to bring a platform that helps the customer to compare all the insurance policies available in the market and make smart choice. It has 93.4% market share of online insurance sales in India. 

Latest Stock News: 

PB Fintech, the parent company of Policybazaar and Paisabazaar, has reported a net profit of 71.54 crore in Q3FY25, a sharp turnaround from a net profit of Rs38.05 crore in the same period last year. Revenue from operations grew 48.31% YoY to 1,291.62 crore.  PB Partners, the company’s agent aggregator platform, now covers 17,100 pin codes, reaching over 90% of India. The company also reported 2.4x YoY growth in UAE insurance premiums in Q3. Meanwhile, GST officials raided PB Fintech’s Gurugram office on January 13, 2025, focusing on vendors linked to PB Partners. The company stated full cooperation with authorities and confirmed no financial impact from the raid, though further details remain undisclosed. 

Potentials: 

PB Fintech has strong growth potential, driven by its improving financials, market leadership, and expanding presence in the digital insurance and lending sectors. With a ₹71.54  crore net profit in Q3FY24 and 48.31%YoY revenue growth, the company is on a positive trajectory. Policybazaar dominates the Indian online insurance aggregator space with 93% market share, while Paisabazaar leads in digital lending, giving PB Fintech a significant competitive edge. Additionally, its expansion into the UAE market with 2.4x YoY premium growth signals international growth opportunities. However, the company faces key risks, including regulatory scrutiny, highlighted by the recent GST raid, and increasing competition from fintech startups and traditional financial institutions. Disruptive technologies like AI, blockchain, and DeFi could reshape the industry, requiring PB Fintech to continuously adapt. Furthermore, like P2P lending platforms, the company must balance risk and return in digital lending, with potential stricter consumer protection laws affecting growth. Economic volatility, changing interest rates, and fluctuations in consumer credit demand could also impact performance. To sustain growth, PB Fintech must proactively navigate regulatory challenges, enhance risk management, and diversify revenue streams while staying ahead of technological disruptions.  In Q2 FY25, the company introduced PaisaSave, a feature-rich co-branded credit card, and in Q3 FY25, it announced the beta launch of PB Money, a personal finance management tool built on the AA ecosystem. 

Analyst InsighAnalyst Insights: 

Key Financial Metrics (Q3FY24): 

  • Revenue: ₹1,292 crore (+49% YoY) 
  • Net Profit: ₹72 crore (vs. ₹60 crore  in Q3FY24) 
  • Adjusted EBITDA: ₹28 crore (13% margin, improved YoY) 
  • Market Cap: ₹ 8,473 Cr.crore 
  • P/E Ratio: 8.7 

Investment Outlook & Opinion: 

PB Fintech, the company, is almost debt-free, and it has produced good quarter results as per the market expectation. Its market leadership in digital insurance (Policybazaar) and lending (Paisabazaar), along with expansion into the UAE, provides long-term growth potential. But the regulatory risks (such as the recent GST raid) and competition from new-age fintech firms pose challenges. The company’s high valuation (P/B at 11.5x) suggests that much of its growth is already priced in, leaving limited room for upside unless profitability scales further. 

Coal India Ltd
Coal India Ltd: Strong Potential, 30% Below ATH, Best Long-Term Picks

Business and Industry Overview

Coal India Limited (CIL) is the world’s largest coal producer. It was established in November 1975 & is classified as a ‘Maharatna’ enterprise under the Ministry of Coal, which means it has operational and financial autonomy. The company is headquartered in Kolkata and operates across eight Indian states. It has a total of 313 active mines, including 131 underground, 168 opencast, and 14 mixed mines. CIL has twelve subsidiaries and five joint venture companies that oversee the coal production across India.  

India aims to achieve a $5 trillion economy by 2025–26, with the coal sector playing a crucial role in ensuring energy security and driving economic growth, particularly in support of the thermal power sector. As the second-largest coal producer in the world, India produced 997.25 million tonnes (MT) of coal in 2023-24, reflecting an 11.65% increase. Coal India Limited contributed 773.647 MT, achieving a growth rate of 10.02%, while the Singareni Collieries Company Limited produced 70.02 MT, with a growth rate of 4.30%. Increased coal demand is anticipated from the electric vehicle sector and the chemicals industry as well. 

India may be pushing for a greener future, but coal still powers 72% of its electricity needs. As global narratives focus on renewables, coal is still responsible for 49% of India’s installed power capacity and generates over 70% of the country’s electricity. Coal India Limited (CIL) is the largest coal producer globally, supplying around 82% of India’s coal output and fulfilling 40% of energy needs. India is also working to minimise coal imports, with thermal coal imports decreasing by about 2% in 2024 due to enhanced domestic production and high inventory levels. Geopolitical factors are affecting global coal trade, with potential increases in U.S. coal exports to India. Despite ongoing efforts to diversify energy sources, coal continues to be a key component of India’s energy strategy, especially in the context of economic growth and environmental considerations. 

Latest Stock News

Southeastern Coalfields Limited (SECL), a subsidiary of Coal India Limited, has increased its budget for corporate social responsibility (CSR) activities, allocating ₹170 crore for the fiscal year 2025. This is an increase from the previous statutory budget of ₹99.76 crore. SECL operates 64 coal mines, with 39 located in Chhattisgarh and the remainder in Madhya Pradesh. The funding will primarily focus on improving health, education, and skill development in the region, with projects expected to be implemented over the next 2 to 3 years.  

Additionally, SECL signed a Memorandum of Understanding (MoU) worth ₹77 crore in 2025 for these initiatives. Among the notable projects is the provision of a 3.0 Tesla MRI machine for the Late Bisahu Das Mahant Memorial Medical College in Korba, which will cost approximately ₹28.08 crore. SECL is also earmarking ₹30.92 crore in financial assistance to the Vidisha district administration in Madhya Pradesh to address malnutrition and stunting, as well as screening for anemia and sickle cell anemia. 

In the October to December quarter of the financial year 2024-25, Coal India reported a net profit of ₹8,491.22 crore, reflecting a 17.5% decline compared to ₹10,291.71 crore in the same quarter the previous year. 

 On a sequential basis, the profit after tax (PAT) surged by 35% compared to the ₹6,289 crore reported in the second quarter of FY25. The company’s topline also increased by 17%, rising from ₹30,672 crore in the July-September quarter. 

On Monday, the state-run miner announced a 17% year-on-year decrease in its consolidated net profit for the December quarter, which stood at ₹8,506 crore compared to ₹10,253 crore in the same period last year. However, the profit after tax exceeded market expectations, which were estimated at ₹8,083 crore. 

Potentials

CIL’s coal production increased by 2% from last year to 543 million tonnes, but land issues and heavy rainfall affected growth. As a result, CIL has lowered its production target for FY25 to about 806 million tonnes, down from an earlier estimate of 838 million tonnes. Despite this, CIL aims to reach a target of 1,000 million tonnes by FY27, with a growth rate of about 6% annually to reach 925 million tonnes. 

CIL is also expanding its business beyond traditional coal mining. It is working on coal gasification projects with BHEL and GAIL, supported by about ₹1,350 crores in financial incentives for each project. CIL has signed an agreement with BPCL to create a coal-to-synthetic natural gas project and is investing in thermal power generation and renewable energy projects like Mahanadi Basin Power Ltd. Additionally, CIL is exploring opportunities to acquire and mine critical minerals in both domestic and international markets. These initiatives are expected to benefit CIL in the long run.The company is nearly debt-free.  

Coal India is anticipated to report a year-on-year (YoY) decline in its net profit for the quarter ending December 2024, primarily due to reduced realizations from weaker e-auction premiums. The board of directors will meet today, January 27, to review and approve the financial results for the third quarter of FY25.  

While a YoY drop in net profit is expected, there may be sequential growth compared to the previous quarter. Revenue for Q3 FY25 is projected to decrease YoY but increase sequentially. Flat volumes, lower blended realizations, and a slight rise in costs are expected to negatively impact operating profit.  

Additionally, Coal India’s board may consider declaring the second interim dividend for the fiscal year 2024-25. The record date for the dividend is set for January 27, 2025. Ahead of the Q3 results announcement, Coal India’s share price was trading down by one percent on Monday. 

Analyst Insights

The market capitalisation of Coal India Limited stands at ₹2,20,472 crore. The stock has a price-to-earnings (P/E) ratio of 6.34 and a book value of ₹156. Investors can expect a dividend yield of 7.19%. Additionally, the return on capital employed (ROCE) is an impressive 63.6%, while the return on equity (ROE) is 52.0%.The stock offers a solid dividend yield of 7.14%. The company has an impressive track record of return on equity (ROE), with a 3-Year ROE of 52.8%. Additionally, it has maintained a healthy dividend payout ratio of 49.8%. 

Coal India presents a strong investment opportunity with a dividend yield of 7.19%, making it attractive for income-focused investors. Its low P/E ratio of 6.34 suggests that the stock may be undervalued compared to its peers. The company’s high return on capital employed (ROCE) of 63.6% and return on equity (ROE) of 52.0% reflect efficient capital utilization and strong profitability. Additionally, Coal India has a consistent dividend payout ratio of 49.8%, providing stable returns for investors. 

However, there are potential risks to consider. Being a public sector unit (PSU), Coal India is dependent on government policies, which exposes it to regulatory risks. Furthermore, environmental concerns and the ongoing transition to renewable energy sources pose long-term risks for coal demand. The cyclical nature of commodities also means that prices and demand for coal can fluctuate significantly.  

In conclusion, the recommendation is to BUY if you are a dividend investor looking for stable cash flows and undervalued stocks. Alternatively, consider HOLDING if you already own the stock, as its fundamentals remain strong but long-term risks are present. 

Glenmark Pharma Ltd
Glenmark Pharma Q3 Results: Smart Recovery with ₹ 348 Crore Net Profit Driven by Higher Revenues

Business and Industry Overview: 

Glenmark Pharmaceuticals is a global research-driven pharmaceutical company. It was founded in 1977 by Gracias Saldanha as a company that makes generic drugs and active pharmaceutical ingredients. It is a research-focused global pharmaceutical company involved in branded, generic, and OTC products. The company focuses on Respiratory, Dermatology, and Oncology therapies. It has four research and development centres and ten top-quality manufacturing facilities on five continents, operating in over eighty countries. By using its strengths in innovation and research, the company aims to challenge traditional treatments and find new solutions that truly help patients around the world. By 2008, Glenmark was the fifth-largest pharmaceutical company in India.  

India is the largest global supplier of generic drugs and is well-known for its affordable vaccines and generic medications. The Indian pharmaceutical industry is currently ranked third in the world in terms of pharmaceutical production by volume. Over the past nine years, this sector has flourished, with a compound annual growth rate (CAGR) of 9.43%.  Key segments within the Indian pharmaceutical industry include generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research and manufacturing, biosimilars, and biologics. India has the highest number of pharmaceutical manufacturing facilities that comply with the standards set by the U.S. Food and Drug Administration (USFDA).  Glenmark Pharmaceuticals is the e 14th largest and fastest growing pharmaceutical company in India and 15th largest generic company in the United States by prescriptions filled & 5th largest generic company in Europe.  

Latest Stock News: 

The company reported consolidated revenue of Rs. 33,876 million which is YoY growth of 35.1% for Q3FY25.  Its Europe Business YoY growth of 14.8% and  India Business at Rs. 10,637 million. The EBITDA of this quarter is at Rs. 6,002 million , with EBITDA margin of 17.7%  The PAT is at Rs. 3,480 Mn with a margin of 10.3%. Glenmark Pharmaceuticals announced the launch of Lacosamide Oral Solution, 10 mg/mL in December 2024. Lacosamide is a medication used to treat and prevent seizures, also known as convulsions, in individuals with epilepsy. This has helped the company with a surge in its price following its announcement in December 2024.  

Segmental information: 

  • Branded Generics: he company has a strong presence in emerging markets, concentrating on its core therapeutic areas. 
  • Dermatology: It is a market leader with the Candid anti-fungal range, which is a significant contributor to its success.  
  • Respiratory: The company is expanding its offerings in respiratory care by providing affordable inhalers and treatments. 
  • Oncology: There is a growing pipeline of cancer treatments designed to enhance its oncology portfolio. 
  • Consumer Healthcare: The company offers over-the-counter (OTC) products such as Scalpe+ anti-dandruff shampoo. 

Subsidiary Information:   

  • Glenmark Holding SA La Chaux-de-Fonds 
  • Glenmark Dominicana SRL 
  • Glenmark Pharmaceuticals Egypt S.A.E. 
  • Glenmark Pharmaceuticals Colombia SAS, Colombia 
  • Glenmark Pharmaceuticals FZE 
  • Glenmark Pharmaceuticals (Australia) Pty Ltd 
  • Glenmark Pharmaceuticals Kenya Ltd 
  • Glenmark Pharmaceuticals Malaysia Sdn Bhd 
  • Glenmark Pharmaceuticals B.V. 
  • Glenmark Pharmaceuticals Distribution s.r.o. 
  • Glenmark Pharmaceuticals Europe Ltd. 
  • Glenmark Pharmaceuticals (Europe) R&D Ltd. 
  • Glenmark Pharmaceuticals Singapore Pte. Ltd. 
  • Glenmark Pharmaceuticals S.R.O. 
  • Glenmark Philippines Inc. 
  • Glenmark Pharmaceuticals (Thailand) Co. Ltd. 
  • Glenmark Pharmaceuticals (Nigeria) Ltd 
  • Glenmark Pharmaceuticals Venezuela, C.A 
  • Glenmark South Africa Proprietary Limited 
  • Glenmark Pharmaceuticals South Africa Proprietary Limited 
  • Glenmark Life Sciences Limited 
  • Glenmark Arzneimittel GmbH 
  • Glenmark Farmaceutica Ltda 
  • GLENMARK PHARMACEUTICALS SP. Z O.O 
  • VISO Farmaceutica S.L.U 
  • Glenmark Pharmaceuticals SK SRO 
  • Glenmark Pharmaceuticals Inc. 
  • Glenmark Uruguay S.A. 
  • Glenmark Pharmaceuticals Canada Inc. 
  • Glenmark Pharmaceuticals Nordic AB 
  • Glenmark Ukraine LLC 

Q3 Highlights: 

  • Consolidated Revenue of Rs. 33,876 million with YoY growth of 35.1% 
  • Europe Business YoY growth of 14.8%  
  • India Business at Rs. 10,637 million 
  • EBITDA at Rs. 6,002 million, with EBITDA margin of 17.7%  
  • PAT at Rs. 3,480 million with a margin of 10.3% Other Highlights  
  • R&D Expenditure of Rs. 2,249 Mn (6.6% of revenue) 

Financial Summary: 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 2,507.00 3,388.00 11,583 11,813 
Expenses 2,715 2,787 9,948 10,618 
EBITDA -209 600 1,635.00 1,195.00 
OPM -8% 18% 14% 10% 
Other Income 87 31 -10 336 
Net Profit -331.00 348.00 377 -1,434 
NPM -13.20 10.27 3.25 -12.14 
EPS -12.45 12.33 24% -5% 
Indian Oil Corporation
Indian Oil Corporation Stock Analysis: 52-Week Low and It Remains a Quality Stock

Business and Industry Overview: 

Indian Oil Corporation Limited is the leading oil and gas-producing PSU in India. The company is under the ownership of the government of India and the Ministry of Petroleum & Natural Gas. It is the largest in terms of both capacity and revenue, with a refining capacity of 80.55 MMTPA. IOCL offers a diverse range of products that include oil, gas, petrochemicals, and alternative energy sources. It has over 37500 fuel stations across the country. The company is well-known for its advanced technologies and innovative research and development in the petrochemical industry. It was ranked 116th on Fortune’s 2022 Global 500 list of the world’s largest corporations. It has maintained its leadership in the ‘BW Top 500’ for the third consecutive year and has been recognized as the most respected oil and gas company by Business World. The company aims at achieving net zero emissions by 2046. It is pioneering green initiatives, including Hydrogen Mobility, hydrogen Transportation, Biofuels, Electric Mobility, Solar Cooktop,s and Minimising Water footprints, which are central to our strategic vision for a cleaner energy future. 

With India targeting to achieve a $5 trillion economy by 2025–26, there is a huge surge in the petrochemical industry to fulfil the demand of the growing economy. Petrochemicals would fuel various industries that will contribute to the growth of the economy, such as agriculture, automotive, packaging, construction, manufacturing, and many more. Hence, this industry cannot be ignored, and the petrochemical demand is expected to reach $1 trillion by 2040. Recently, the Government of India has taken various initiatives, including 100% FDI through automatic routes, establishing Petroleum, Chemicals, and Petrochemicals Investment Regions (PCPIRs). It is also setting up infrastructure like 10-plus plastic parks which are to be executed between 2020 and 2035. IOC being one of the leading petrochemical producer companies in India, has a 42% market share in petroleum Oil and lubricants with over 60,900 touch points. It owns 11 refineries across India. It also has its subsidiary functioning across India like IndianOil (Mauritius) Limited,  Lanka IOCPLC  in Sri Lanka, 10C Middle East FZE , 10C Sweden AB , IOCL (USA) Inc. are few of them.  

Latest Stock News: 

ADNOC Gas (Abu Dhabi National Oil Company), a natural gas producer based in Abu Dhabi, UAE, has signed a long-term sales and purchase agreement (SPA) with Indian Oil Corporation Ltd. to supply liquefied natural gas (LNG) for 14 years. This agreement is valued between $7 billion and $9 billion and will commence in 2026, providing IndianOil with up to 1.2 million metric tonnes of LNG annually. The agreement supports India’s objective of increasing the share of gas in its energy mix to 15% by 2030 and demonstrates ADNOC Gas’s commitment to lower-carbon energy solutions. The LNG will be sourced from ADNOC Gas’s Das Island facility, which has a production capacity of 6 million metric tonnes per year and a proven track record of reliability. 

This deal is part of ADNOC Gas’s strategy to secure long-term contracts in growing Asian markets, diversifying sources beyond traditional suppliers like Qatar and Russia, and thereby strengthening India’s energy security. Additionally, the agreement reinforces India’s strategic partnership with the UAE, a key supplier of crude oil, and opens up opportunities for further investments in refining, petrochemicals, and renewable energy. 

Indian Oil Corporation is trading -0.64% lower at Rs 116.50 as compared to its last closing price. Indian Oil Corporation has been trading in the price range of 117.55 & 114.35. Indian Oil Corporation has given -14.05% in this year & -6.28% in the last 5 days. Indian Oil Corporation has TTM P/E ratio 17.67 as compared to the sector P/E of 8.97.  

Potentials: 

The Indian government is actively working to increase the share of natural gas in the country’s energy mix from 6% to 15% by 2030 as part of its clean energy transition. Aligning with this vision, Indian Oil Corporation (IOCL) has signed a 14-year sales and purchase agreement with ADNOC Gas to import liquefied natural gas (LNG), ensuring a stable and long-term supply to meet rising domestic demand. From a valuation perspective, IOCL’s stock is currently trading at 0.90 times its book value, indicating it is relatively undervalued compared to its intrinsic worth. The company also offers an attractive dividend yield of 10.2%, making it appealing to income-focused investors. Over the past five years, IOCL has demonstrated strong profit growth, delivering a CAGR of 19.1%, reflecting its operational efficiency and strategic expansion. Additionally, the company has maintained a healthy dividend payout ratio of 42.6%, ensuring consistent returns for its shareholders while balancing reinvestment in growth initiatives. 

Analyst Insights: 

On Monday, Indian Oil Corporation announced a 76.57% decline in its consolidated net profit, totalling Rs 2,115 crore for the third quarter (Q3) of the financial year 2024-25 (FY25), down from Rs 9,029.56 crore for the same period last year. The significant decrease in profits was attributed to diminished refining margins and increased expenses during the quarter. The Consolidated operational revenue saw a slight dip of 5% to Rs 2,15,522 crore, compared to Rs 2,26,892 crore reported in the same quarter a year earlier. 

Expenses remained largely unchanged at Rs 2.19 trillion, up slightly from Rs 2.17 trillion. However, compared to the previous quarter, expenses increased by 8.4% from Rs 2.02 trillion. The market capitalization of Indian Oil is ₹ 1,64,654 Cr, with a stock P/E of 17.0 and ROCE of 21.1%. 

With the volatility in the oil and gas industry, the investors should hold the security for now and keep an eye on the changing market as there is a drop in the profit margin and since this industry is cyclical. The P/E ratio is 17 compared to the industry which is 18.95 and the ROCE is 21.1 which means that the comapy can generate good return on the capital employed.  

SJVN Ltd
SJVN Ltd Q3 Results: Net Profit Up 7%, Revenue Growth & Interim Dividend Declared

Business and Industry Overview: 

SJVN Limited is a Nava Ratna, Category-I, and Schedule ‘A’ Central Public Sector Enterprise (CPSE) under the Ministry of Power, Government of India, incorporated on May 24, 1988, as a joint venture between the Government of India and the Government of Himachal Pradesh. The company has a shareholder pattern of 64.46% from the Government of India, 25.51% from the Government of Himachal Pradesh, and 10.03% from the public, with a paid-up capital of Rs. 4,136.63 Crore and an authorized capital of Rs. 7,000 Crore. SJVN was conferred with Navratna status on August 30, 2024. Initially starting with the Nathpa Jhakri Hydro Power Station (1500 MW) in Himachal Pradesh, SJVN has since commissioned a total of 14 projects, amounting to 2467 MW of installed capacity. The company is currently implementing power projects across various states in India, including Himachal Pradesh, Uttarakhand, Bihar, Maharashtra, Uttar Pradesh, Punjab, Gujarat, Arunachal Pradesh, Rajasthan, Assam, Odisha, Mizoram, and Madhya Pradesh, as well as in Nepal. A significant milestone includes the commissioning of the 400 kV double circuit Indo-Nepal Cross Border Power Transmission corridor on February 19, 2016, along with ongoing work on a 217 km long transmission line from Arun-3 HEP to the Indo-Nepal border. 

Latest Stock News: 

SJVN Ltd, a hydropower public sector unit, reported a 7% increase in consolidated net profit, reaching Rs 148.75 crore for the December quarter. This rise is attributed to higher revenues, as the company posted a net profit of Rs 138.97 crore during the same period last year, according to a filing with the Bombay Stock Exchange (BSE).  

Total income for the quarter rose to Rs 760.76 crore, up from Rs 607.72 crore in the previous year.  

The board of directors has also approved an interim dividend of Rs 1.15 per equity share for the 2024-25 financial year. The record date for the interim dividend is February 21, 2025, and dividend payments will commence from March 6, 2025, onwards. 

Currently, the company’s shares are trading 2.60% lower at Rs 90.22, with a dividend yield of 1.99%. 

Segmental information:

1. Electricity Generation: 

Hydroelectric Power: SJVN’s core competency lies in hydroelectric power generation. The company operates significant projects, including the 1,500 MW Nathpa Jhakri Hydro Power Station and the 412 MW Rampur Hydro Power Station, both located in Himachal Pradesh. These facilities harness river water to produce renewable energy. citeturn0search12 

Wind Power: Expanding into wind energy, SJVN has commissioned projects like the 47.6 MW Khirvire Wind Power Project in Maharashtra and the 50 MW Sadla Wind Power Project in Gujarat. These installations utilize wind resources to generate electricity. citeturn0search0 

Solar Power: SJVN has ventured into solar energy with projects such as the 75 MW Parasan Solar Power Project in Uttar Pradesh and the 5.6 MW Charanka Solar Power Project in Gujarat. These solar installations contribute to the company’s renewable energy portfolio. citeturn0search12 

2. Consultancy Services: Leveraging its expertise in power generation, SJVN offers consultancy services encompassing project planning, feasibility studies, engineering, procurement, construction management, and operational support. These services cater to other entities in the power sector, facilitating the development of energy projects.  

3. Power Transmission: SJVN is involved in the transmission of electricity, ensuring efficient delivery from generation sites to distribution networks. This includes the construction, operation, and maintenance of transmission lines and substations, playing a crucial role in the power supply chain. citeturn0search1 

4. Power Trading:To optimize its energy portfolio, SJVN engages in power trading activities. This involves the buying and selling of electricity, allowing the company to respond to market dynamics, balance supply and demand, and enhance revenue generation. citeturn0search1 

5. Project Development and Execution: Beyond operating existing facilities, SJVN is actively involved in developing new power projects. This includes identifying potential sites, securing necessary approvals, and overseeing the construction and commissioning of new power plants across various energy sectors.  

Subsidiary Information:

SJVN Arun-3 Power Development Company Pvt. Ltd. (SAPDC) : A wholly owned subsidiary established in Nepal for the implementation of the 900 MW Arun-3 Project and its associated transmission system. 

SJVN Lower Arun Power Development Company Private Limited (SLPDC) : A fully owned subsidiary created for the development of the 669 MW Lower Arun Hydro Electric Project (HEP) in Nepal. 

 SJVN Thermal Private Limited (STPL) : A wholly owned subsidiary formed for the execution of the 1320 MW Buxar Thermal Power Project in Bihar. 

SJVN Green Energy Limited (SGEL) : A fully owned subsidiary established to focus on capacity additions in new and renewable energy sources. 

Joint Ventures  

Cross Border Power Transmission Company Limited (CPTC) : A joint venture among IEDCL, Power Grid, SJVN, and NEA with equity participation of 38%, 26%, 26%, and 10%, respectively. This venture aims to construct and maintain an 86 km long, 400 kV double circuit (D/C) transmission line from Sursund on the India-Nepal border to Muzaffarpur. 

Q3 Highlights:

  • SJVN Ltd Q3 results: Net profit rises by 7% to Rs 149 crore on higher revenue 
  • The board of directors has also approved an interim dividend of Rs 1.15 per equity share for 2024-25. 
  • SJVN Ltd Q3 results Net profit rises by 7 to Rs 149 crore on higher revenue 
  • The board of directors approved an interim dividend of Rs 1.15 per equity share for the 2024-25 financial year. 

Financial Summary:

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 543.00 671.00 2,938 2,579 
Expenses 175 214 665 737 
EBITDA 368 457 2,273.00 1,843.00 
OPM 68% 68% 77% 71% 
Other Income 49 91 310 380 
Net Profit 139.00 149.00 1,359 911 
NPM 25.60 22.21 46.26 35.32 
EPS 0.35 0.38 3.46 2.32 
CRISIL Ltd
CRISIL Q3 Results: Net Profit Rises 7% to ₹225 Crore, Revenue Flat – Full Analysis

CRISIL Ltd: Business and Industry Overview 

CRISIL Ltd started in 1987, with collaboration between ICICI (Industrial Credit and Investment Corporation of India) and UTI (Unit Trust of India). CRISIL was the first credit rating agency in India. The operational segments of CRISIL are Research, Benchmarking, Consulting services and Analytics. It has expanded its footprint in multiple countries around the globe in USA, Europe, Middle East, Australia, and countries of Asia, serving many international big clients. CRISIL was later demerged from ICICI and was acquired by a US company S&P Global Ltd a credit scoring company. It has established really strong brands under its umbrella to expand in many service segments to become Ace. It started CRISIL Ratings, CRISIL Intelligence for market intelligence and analytics business segment, CRISIL Integral IQ and many more. It has total of 4600+ employees working over 12 countries. As this year’s government budget is more favoured towards consumption side, which will increase the money circulation in economy and will eventually result in higher inflation. CRISIL expects India’s GDP growth to be 6.5% for next fiscal year. It thinks bond issuances may experience tailwinds driven by easing in monetary policies. The industrial lending segment in short future will stay range bound but the personal lending portfolio of banks might see an increase.  

Latest Stock News 

Investors prefer the high quality of CRISL’s rating which has given CRISIL Ratings services a leading position in corporate bond segment. Research, Analytics and Solutions saw demand in buy-side offerings, consulting, and credit and risk offerings from global clients. In Q4 FY23, company saw gain of ₹29.4 crore due to sharp devaluation of Argentinian peso, and if we exclude that then PBT grew by 18.1% in this quarter YoY. Final dividend of ₹26 per share was declared, making the total dividend of ₹56 per share this year compared to ₹54 in FY23. It has recognized as a category leader in Chartis’ RiskTechCredit Portfolio Management (CPM) Solutions 2024 Quadrant, receiving 15 recognitions. To engage with clients it hosted 9th annual NBFC seminar in Mumbai, hosted conclave in real estate segment with title of ‘Shaping the Future of Real Estate’. CRISIL Coalition Greenwich hosted competitive challenges for asset managers in Chicago. CRISIL Integral IQ sponsored risk finance events focusing on trends in model risk, investment risk, impact of AI and technology, etc. During this quarter, CRISIL Foundation expanded its outreach and provided help to more than 4 lakh rural community members in Assam and Rajasthan under its flagship program ‘Mein Pragati’. 

Segment Information 

  • Ratings Services: This subsidiary provides ratings, which can help the issuers for funding and also for borrowers. Its services give an internal evaluation processes which includes screening of companies to ensure their operations and capabilities to repay or provide funding. Its services are majorly use in calculating the capital adequacy of banks. It has given rating to over 7000+ large and medium corporates and financial institutions. 
  • Research, Analytics and Solutions: It helps its clients with making strategic decisions, as it is expertise in collecting data and providing solutions to make companies grow their business and revenues. It has also worked with Indian Government as a support in making of PPP framework for India. Its services are offered in Asia, Africa and Middle East countries. It is the official rating provider of Indian Mutual Funds and a largest provider for fixed income valuations in India, covering more than ₹197 trillion. It also launched India’s first AIF benchmark to help AIF portfolios to compare their performance. 
  • International Business: It is a leading strategy implementation partner that works across globe helping companies in mitigating risks, make better decision, productive environment and enhance their returns. It serves 15 leading global investment bankers, 5 leading insurers, 40 credit risk teams of global banks.  

Subsidiaries Information 

  • CRISIL ESG Ratings & Analytics Ltd: This subsidiary provides ratings to companies and to banks globally for its credit lending or funding services helping them to optimize their capital. CRISIL ESG Ratings is registered with SEBI as a ‘Category 1’ ESG rating provider (ERP). It serves major banks, institutional and retail investors, asset managers, Mutual Funds and asset managers. 
  • Bridge to India Energy Private Limited: It is the leading consultancy and knowledge services provider in Indian renewable energy market. It provides wide range of services of consulting and research to contractors, companies, banks, government agencies, developers, financial institutions, etc. It is taking benefit of the comprehensive database it has to provide research and help their clients to grow and make the industry better. 
  • CRISIL Irevna Information Technology Columbia S.A.S: This subsidiary is based in Columbia, where many financial and technological professors work. It takes the outsourcing work of some key North American clients and helps them by providing research and strategic decision to grow their business. CRISIL has commenced a new unit in Columbia in Bogota to help them offer more services to their international clients. 
  • CRISIL Ratings Ltd: This subsidiary provides rating services to banks, financial institutions, mutual funds to rate their debt funding which will enhance the information making easy to invest or lend. Issuers and borrowers leverage its ratings to access funding, widening range of funding alternatives and optimize their capital. Government has made it compulsory for each mutual fund to have ratings, so that investors can make informed investments. 

Q3 FY25 Earnings 

  • Revenue of ₹913crore in Q3 FY25 down by 0.43% YoY from ₹917 crore in Q3 FY24.  
  • EBITDA of ₹317.7 crore in this quarter at a margin of 34.8% compared to 38.1% in Q3 FY24. 
  • Profit of ₹224.7 crore in this quarter compared to a ₹210 crore profit in Q3 FY24. 

Financial Summary 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 913 917 3139 3259 
Expenses 648.7 672.1 2365.5 2423 
EBITDA 317.7 349.4 975.1 1000 
OPM 34.8% 38.1% 31% 30.7% 
Other Income 30.2 33.2 93.6 89.6 
Net Profit 224.7 210.2 658 684 
NPM 24.6% 22.9% 20.9% 20.9% 
EPS 30.72 28.74 90.1 93.55 
GSK Pharma Ltd
GlaxoSmithKline Pharma Q3 Results: Strong Net Profit Soars 400% to ₹228.58 Cr, Revenue Up 18% YoY

Business and Industry Overview: 

GlaxoSmithKline Pharmaceuticals Limited (GSK Pharmaceuticals) is a leading research-based pharmaceutical and healthcare company in India, functioning as a subsidiary of the global entity GSK plc. Founded on November 13, 1924, originally as H.J. Foster & Co. Limited, the company has transformed over the decades into a significant player in India’s pharmaceutical sector. GSK is recognized as one of the top 10 drug manufacturers worldwide. In India, GSK’s operations include General Medicines, Pediatric Vaccines, and Adult Vaccines. The company’s Respiratory portfolio features products like Nucala and Trelegy, while its Adult Immunization category includes the Shingrix Herpes Zoster Vaccine. GSK is also implementing an omnichannel strategy to enhance its reach and service coverage. As of 2024, GSK’s net asset value was approximately 128 million Indian rupees. The company’s future performance may fluctuate due to various factors, including changes in industry trends, market conditions, government regulations, and other unforeseen circumstances. 

India is the largest global supplier of generic drugs and is well-known for its affordable vaccines and generic medications. The Indian pharmaceutical industry is currently ranked third in the world in terms of pharmaceutical production by volume. Over the past nine years, this sector has flourished, with a compound annual growth rate (CAGR) of 9.43%.  Key segments within the Indian pharmaceutical industry include generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research and manufacturing, biosimilars, and biologics. India has the highest number of pharmaceutical manufacturing facilities that comply with the standards set by the U.S. Food and Drug Administration (USFDA). The country is home to numerous producers, which account for approximately 8% of the global active pharmaceutical ingredient (API) market. GSK is the leading player in this market, boasting a market share of 33%. 

Latest Stock News: 

GlaxoSmithKline (GSK) Pharmaceuticals announced an impressive 402% year-on-year (YoY) increase in consolidated net profit for the December quarter (Q3 FY25), reaching ₹228.58 crore, up from ₹45.49 crore in the same period last year. On February 14, GSK Pharmaceuticals reported an 18% revenue increase to ₹946 crore for the quarter ending December 31, 2024, along with a profit after tax of ₹229 crore. 

During this quarter, the company’s revenue from operations rose to ₹946.36 crore, reflecting a 17.5% YoY increase from ₹804.98 crore in Q3 FY24.  

However, compared to the previous quarter, the company experienced a decline: net profit fell by 8.08%, and revenue decreased by 5.4%, down from ₹248.68 crore and ₹1,000.05 crore reported in Q2 FY25, respectively. 

Segmental information:

Pharmaceuticals: GSK Pharmaceuticals offers a diverse range of prescription medicines across various therapeutic areas, including anti-infectives, dermatology, gynecology, diabetes, oncology, cardiovascular diseases, and respiratory ailments. 

Key Products: The company’s portfolio features leading brands such as Augmentin, a widely used antibiotic, and respiratory therapies like Nucala and Trelegy. These products have significantly contributed to the company’s growth, with Augmentin maintaining its position as the No.1 brand in the Indian pharmaceutical market.  

Pediatric Vaccines: GSK Pharmaceuticals provides vaccines aimed at preventing diseases such as hepatitis A and B, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, and cervical cancer. The pediatric vaccine portfolio has demonstrated double-digit growth, maintaining market leadership in the private sector. 

Adult Vaccines: The company is advancing adult immunization in India, notably with Shingrix, a vaccine for shingles. Innovative marketing strategies, including awareness campaigns featuring prominent figures, have bolstered the uptake of adult vaccines.  

Subsidiary Information:

ViiV Healthcare: Specializing in HIV treatment and prevention, ViiV Healthcare is a joint venture where GSK plc holds a majority stake of 76.5%, while Pfizer and Shionogi own 13.5% and 10%, respectively. This collaboration focuses on delivering advanced HIV therapies worldwide. 

Stiefel Laboratories: Acquired by GSK in 2009, Stiefel Laboratories specializes in dermatology products, thereby enhancing GSK’s portfolio in skin-related treatments. 

Reliant Pharmaceuticals: Purchased by GSK in 2007, Reliant Pharmaceuticals contributed a range of cardiovascular products, including Lovaza, an omega-3-acid ethyl ester, to GSK’s portfolio. 

Haleon: In July 2022, GSK plc demerged its consumer healthcare business to form Haleon, which focuses on over-the-counter products and wellness. This strategic move allowed GSK to concentrate more on its biopharmaceutical segments. 

Q3 Highlights:

  • GSK Pharmaceuticals reported a 402% YoY increase in net profit for Q3 FY25, totaling ₹228.58 crore (up from ₹45.49 crore last year).  
  • Revenue for the December 2024 quarter rose 18% to ₹946 crore. Revenue from operations increased by 17.5% YoY to ₹946.36 crore, compared to ₹804.98 crore in Q3 FY24.  
  • Compared to Q2 FY25, net profit fell by 8.08% and revenue decreased by 5.4% (down from ₹248.68 crore and ₹1,000.05 crore, respectively). 

Financial Summary:

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 805.00 949.00 3,252 3,454 
Expenses 587 658 2,447 2,545 
EBITDA 218 292 804.00 909.00 
OPM 27% 31% 25% 26% 
Other Income -135 35 103 -21 
Net Profit 46.00 230.00 611 590 
NPM 5.71 24.24 18.79 17.08 
EPS 2.7 13.57 36.05 34.83